Selective and non-selective non-steroidal anti-inflammatories, administration during pregnancy and breast-feeding;Anti-inflammatoires non stéroïdiens sélectifs et non sélectifs, utilisation au cours de la grossesse et de l'allaitement

Presse Medicale

Volumn 31, Issue 31, 2002, Pages 1462-1468

  Fardet, Laurence ^a   Nizard, Jacky ^a   Généreau, Thierry ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

BREAST FEEDING; FETUS DISEASE; HUMAN; INTOXICATION; OLIGOHYDRAMNIOS; PREGNANCY; PRESCRIPTION; REVIEW; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ABNORMALITIES, DRUG-INDUCED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST FEEDING; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037190481     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Collins E, Turner G. Maternal effects of regular salicylate ingestion in pregnancy. Lancet 1975; 2: 335-7
2. Yegnanarayan R, Joglekar GV. Anti-fertility effect of non-steroidal anti-inflammatory drugs. Jnp J Pharmacol 1978; 28: 909-17 [abstract].
3. Levy G, Garrettson LK. Kinetics of salicylate elimination by newborn infants of mothers who ingested aspirin before delivery. Pediatrics 1974; 53: 201-10.
4. Schoenfeld A, Bar J, Merlob P, Ovadia Y. NSAIDs: maternal and foetal considerations. Am J Reprod Immunol 1992; 28: 141-7.
5. Turner G, Collins E. Fetal effects of regular salicylate ingestion in pregnancy. Lancet 1975; 2: 338-9.
6. Rumack CM, Guggenheim M, Rumack BH, Peterson RG, Johnson ML, Braithwaite WR. Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981; 58: 52-6.
7. Stuart MJ, Gross SJ, Elrad H, Graeber JE. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N Engl J Med 1982; 307: 909-12.
8. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S, Aspirin and congenital malformations. Lancet 1976; 1: 1373-5.
9. CLASP collaborative group. A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619-29.
10. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia (Cochrane review). Cochrane library 2001; 3.
11. Dekker G, Sibai B. Primary, secondary and tertiary prevention of pre-eclampsia. Lancet 2001; 357: 209-15.
12. Lee RM, Silver RM. Recurrent pregnancy loss: summary and clinical recommendations. Semin Reprod Med 2000; 18: 433-40.
13. Sammaritano LR. Update on the management of the pregnant patient with antiphospholipid antibody. Curr Rheumatol Rep 2001; 3: 213-21.
14. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183: 1008-12.
15. Casteels-Van Daele M, Van Geet C, Wouters C, Eggermont E. Reye syndrome revisited: a descriptive term covering a group of heterogeneous disorders. Eur J Pediatr 2000; 159: 641-8.
16. Lee P. Anti-inflammatory therapy during pregnancy and lactation. Clin Invest Med 1985; 8: 328-32.
17. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994; 79: 1165-77.
18. Sonksen JR, Kong KL, Holder R. Magnitude and time course of impaired primary haemostasis in chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth 1999; 82: 360-5.
19. Windle ML, Booker LA, Rayburn WF. Postpartum pain after vaginal delivery. A review of comparative analgesic trials. J Reprod Med 1989; 34: 891-5.
20. Findlay JW, DeAngelis RL, Kearney MF, Welch RM, Findlay JM. Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther 1981; 29: 625-33.
21. Unsworth J, d'Assis-Fonseca A, Beswick DT, Blake DR. Serum salicylate levels in a breast fed infant. Ann Rheum Dis 1987; 46: 638-9.
22. Clark JH, Wilson WG. A 16-day-old breast-fed infant with metabolic acidosis caused by salicylate. Clin Pediatr (Phila)1981; 20: 53-4.
23. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93: 137-50.
24. Katz E, Dharmarajan AM, Sueoka K, Ghodganonkarb RB, Dubin NH, Wallach EE. Effects of systemic administration of indomethacin on ovulation, luteinification, and steroidogenesis in the rabbit ovary. Am J Obstet Gynecol 1989; 161: 1361-6.
25. Biggers JD, Baskar JF, Torchiana DF. Reduction of fertility of mice by the intrauterine injection of prostaglandin antagonists. J Reprod Fertil 1981; 63: 365-72.
26. Poyser NL. A comparison of the effects of indomethacin and NS-398 (a selective prostaglandin H synthase-2 inhibitor) on implantation in the rat. Prostaglandins Leukot Essent Fatty Acids 1999; 61: 297-301.
27. Ratnasooriya WD, Wadsworth RM. Effect on fertility in rats of epididymal administration of indomethacin. Int J Fertil 1987; 32: 152-6.
28. Priddy AR, Killick SR. Eicosanoids and ovulation. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 827-31.
29. Smith G, Roberts R, Hall C, Nuki G. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Br J Rheumatol 1996; 35: 458-62.
30. Akil M, Amos RS, Stewart P. Infertility may sometimes be associated with non-steroidal anti-inflammatory drug consumption. Br J Rheumatol 1996; 35: 76-8.
31. Martin-Du Pan RC, Bischof P, Campana A, Morabia A. Relationship between etiological factors and total motile sperm count in 350 infertile patients. Arch Androl 1997; 39: 197-210.
32. Barkay J, Harpaz-Kerpel S, Ben-Ezra S, Gordon S, Zuckerman H. The prostaglandin inhibitor effect of antiinflammatory drugs in the therapy of male infertility. Fertil Steril 1984; 42: 406-11.
33. Momma K, Takao A. In vivo constriction of the ductus arteriosus by nonsteroidal antiinflammatory drugs in near-term and preterm fetal rat. Pediatr Res 1987; 22: 567-72.
34. Chamaa NS, Mosig D, Drukker A, Guignard JP. The renal hemodynamic effects of ibuprofen in the newborn rabbit. Pediatr Res 2000; 48: 600-5.
35. Levin DL. Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation. Semin Perinatol 1980; 4: 35-44.
36. Klein KL, Scott WJ, Clark KE, Wilson JG. Indomethacin-placental transfer, cytotoxicity and teratology in the rat. Am J Obstet Gynecol. 1981; 141: 448-52.
37. Janssen NM, Genta MS. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation. Arch Intern Med 2000; 160: 610-19.
38. Bivins HA, Newman RB, Fyfe DA, Campbell BA, Stramm SL. Randomized trial of oral indomethacin and terbutaline sulfate for the long-term suppression of preterm labor. Am J Obstet Gynecol 1993; 169: 1065-70.
39. Moise KJ, Huhta JC, Sharif DS et al. Indomethacin in the treatment of premature labor : effects on the fetal ductus arteriosus. N Engl J Med 1988; 319: 327-31.
40. Itskovitz Y, Abramovici H, Brandes JM. Oligohydramnion, meconium and perinatal death concurrent with indomethacin treatment in human pregnancy. J Reprod Med 1980; 24: 137-40.
41. Kirshon B, Moise KJ Jr, Wasserstrum N, Ou CN, Huhta JC. Influence of short-term indomethacin therapy on fetal urine output. Obstet Gynecol 1988; 72: 51-3.
42. Hickok DE, Hollenbach KA, Reilley SF, Nyberg DA. The association between decreased amniotic fluid volume and treatment with nonsteroidal anti-inflammatory agents for preterm labor. Am J Obstet Gynecol 1989; 160: 1525-31.
43. Goldenberg RL, Davis RO, Baker RC Indomethacin-induced oligohydramnios. Am J Obstet Gynecol 1989; 160: 1196-7.
44. Cuzzolin L, Dal Cere M, Fanos V. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf 2001; 24: 9-18.
45. Kaplan BS, Restaino I, Raval DS, Gottlieb RP, Bernstein J. Renal failure in the neonate associated with in utero exposure to non-steroidal anti-inflammatory agents. Pediatr Nephrol 1994; 8: 700-4.
46. Gloor JM, Muchant DG, Norling LL. Prenatal maternal indomethacin use resulting in prolonged neonatal renal insufficiency. J Perinatol 1993; 13: 425-7.
47. Baerts W, Fetter WP, Hop WC, Wallenburg HC, Spritzer R, Sauer PJ. Cerebral lesions in preterm infants after tocolytic indomethacin. Dev Med Child Neurol 1990; 32: 910-18.
48. Major CA, Lewis DF, Harding JA, Porto MA, Garite TJ. Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate. Am J Obstet Gynecol 1994; 170: 102-6.
49. Powell JG Jr, Cochrane RL. The effects of a number of non-steroidal anti-inflammatory compounds on parturition in the rat. Prostaglandins 1982; 23: 469-88.
50. Dudley DK, Hardie MJ. Fetal and neonatal effects of indomethacin used as a tocolytic agent. Am J Obstet Gynecol 1985; 151: 181-4.
51. Vermillion ST, Newman RB. Recent indomethadn tocolysis is not associated with neonatal complications in preterm infants. Am J Obstet Gynecol 1999; 181: 1083-6.
52. Rasanen J, Jouppila P. Fetal cardiac function and ductus arteriosus during indomethacin and sulindac therapy for threatened preterm labor: a randomized study. Am J Obstet Gynecol 1995; 173: 20-5.
53. Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis D. Randomized comparative trial of indomethacin and sulindac for the treatment of refractory preterm labor. Obstet Gynecol 1992; 79: 223-8.
54. Niebyl JR. Preterm parturition. Prostaglandin synthetase inhibitors. Semin Perinatol 1981; 5: 274-87.
55. Townsend RJ, Benedetti TJ, Erickson SH et al. Excretion of ibuprofen into breast milk. Am J Obstet Gynecol 1984; 149: 184-6.
56. Eeg-Olofsson O, Malmros I, Elwin CE, Steen B. Convulsions in a breast-fed infant after maternal indomethacin. Lancet 1978; 2: 215.
57. Scherle PA, Ma W, Lim H, Dey SK, Trzaskos JM. Regulation of cyclooxygenase-2 induction in the mouse uterus during decidualization. An event of early pregnancy J Biol Chem 2000; 275: 37086-92.
58. Davis BJ, Lennard DE, Lee CA et al. Anovulation in cyclooxygenase-2-deficient mice is restored by prostaglandin E2 and interleukin-1 beta. Endocrinology 1999; 140: 2685-95.
59. Lim H, Paria BC, Das SK et al. Multiple female reproductive failures in cyclooxygenase-2-deficient mice. Cell 1997; 91: 197-208.
60. Pall M, Friden BE, Brannstrom M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum Reprod 2001; 16: 1323-8.
61. Clyman RI, Hardy P, Waleh N et al. Cyclooxygenase-2 inhibitor plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am J Physiol 1999; 276: 913-21.
62. Guerquerian AM, Hardy P, Bhattacharya M et al. Expression of cyclooxygenase in ductus arteriosus of fetal and newborn pigs. Am J Obstet Gynecol 1998; 179: 1618-26.
63. Coceani F, Ackerley C, Seidlitz E, Kelsey L. Function of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the ductus arteriosus from foetal lamb: differential development and change by oxygen and endotoxin. Br J Pharmacol 2001; 132: 241-51.
64. Takahashi Y, Roman C, Chemtob S et al. Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol Regul Integr Comp Physiol 2000; 278: 496-505.
65. Locatelli A, Vergani P, Bellini P, Strobelt N, Ghidini A. Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin? BJOG 2001; 108: 325-6.
66. Landau D, Shelef I, Polacheck H, Marks K, Holcberg G. Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use. Am J Perinatol 1999; 16: 441-4.
67. Peruzzi L, Gianoglio B, Porcellini MG, Coppo R. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-2 selective inhibitor nimesulide as tocolytic. Lancet 1999; 354: 1615.
68. Peruzzi L, Gianoglio B, Porcellini G, Conti G, Amore A, Coppo R. Neonatal chronic kidney failure associated to cyclo-oxygenase inhibitors administered during pregnancy. Minerva Urol Nefrol 2001; 53: 113-116 [abstract].
69. Kömhoff M, Wang JL, Cheng HF et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000; 57: 414-22.
70. Sakai M, Tanebe K, Sasaki Y, Momma K, Yoneda S, Saito S. Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery. Mol Hum Reprod 2001; 7: 595-602.
71. Yousif MH, Thulesius O. Tocolytic effect of the cyclooxygenase-2 inhibitor, Meloxicam: studies on uterine contractions in the rat. J Pharm Pharmacol 1998; 50: 681-5.
72. Bukowski R, Mackay L, Fittkow C, Shi L, Saade GR, Garfield RE. Inhibition of cervical ripening by local application of cyclooxygenase 2 inhibitor. Am J Obstet Gynecol 2001; 184: 1374-9.
73. Simon LS, Lanza FL, Lipsky PE et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebocontrolled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591-602.
74. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40: 124-32.